查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463813

全球疤痕治療市場：市場規模和份額分析（按治療類型、疤痕類型和最終用戶）、行業需求預測（截至2030年）

Scar Treatment Market Size and Share Analysis by Treatment Type, Scar Type, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 310 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

主要亮點

2023年，全球疤痕治療市場將達238億美元，2030年將達528億美元，複合年增長率超過12.0%。

人們對疤痕管理的認識不斷提高，大眾對獲得完美肌膚的興趣日益濃厚，對整容手術的需求迅速增加，以及醫療技術的進步正在推動該行業的擴張。

如今已有改良的美容手段，包括雷射、化學換膚、微晶磨皮術和磨皮術。 這些進步使得為改善美觀提供更有效的選擇成為可能。

市場洞察

到 2023 年，北美將成為最大的地區，份額約為 37.8%。

北美地區可支配收入較高，導致個人護理產品成本較高，是該地區產業的主要影響因素。

到 2023 年，美國將成為北美工業的最大貢獻者，並且在這十年中可能會以更快的複合年增長率取得進步。

雷射類別預計將呈現十年來最高成長率，達到 12.7%。 這是因為雷射治療比目前可用的治療更先進。

到 2023 年，萎縮性疤痕和痤瘡疤痕將以 40.1% 的份額主導該行業，並且在這十年中仍將是最大的。

疤痕疙瘩和肥厚疤痕類別預計在未來幾年將以最快的複合年增長率增長。 這是由於手術數量不斷增加以及燒傷和創傷的發生率增加。

本報告分析了全球疤痕治療市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、按地區和主要國家的市場規模前景（以貨幣形式計算） （2017-2030），按治療類型、疤痕類型和最終用戶劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第1章研究範圍

第2章研究方法

第 3 章執行摘要

第 4 章市場指標

第5章產業展望

  • 市場動態
    • 趨勢
    • 促進因素
    • 抑制因素/挑戰
    • 促進/抑制因子影響分析
  • 新型冠狀病毒感染 (COVID-19) 的影響
  • 波特五力分析

第6章世界市場

  • 摘要
  • 市場收入：依治療類型分類（2017-2030 年）
    • 局部治療市場收入：按類型劃分（2017-2030 年）
    • 表面處理市場收入：按類型劃分（2017-2030 年）
    • 雷射治療市場收入：按類型劃分（2017-2030 年）
    • 注射療法市場收入：按類型劃分（2017-2030 年）
  • 市場收入：依疤痕類型分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：按地區劃分（2017-2030 年）

第7章北美市場

  • 摘要
  • 市場收入：依治療類型分類（2017-2030 年）
    • 局部治療市場收入：按類型劃分（2017-2030 年）
    • 表面處理市場收入：按類型劃分（2017-2030 年）
    • 雷射治療市場收入：按類型劃分（2017-2030 年）
    • 注射療法市場收入：按類型劃分（2017-2030 年）
  • 市場收入：依疤痕類型分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第11章中東及非洲市場

第12章美國市場

  • 摘要
  • 市場收入：依治療類型分類（2017-2030 年）
    • 局部治療市場收入：按類型劃分（2017-2030 年）
    • 表面處理市場收入：按類型劃分（2017-2030 年）
    • 雷射治療市場收入：按類型劃分（2017-2030 年）
    • 注射療法市場收入：按類型劃分（2017-2030 年）
  • 市場收入：依疤痕類型分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）

第13章加拿大市場

第14章德國市場

第15章法國市場

第16章英國市場

第17章義大利市場

第18章西班牙市場

第19章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

  • 市場參與者及其產品列表
  • 主要公司的競爭基準
  • 各大公司的產品基準
  • 近期策略發展狀況

第30章公司簡介

  • Avita Medical Inc.
  • Revitol Corporation
  • Sonoma Pharmaceuticals Inc.
  • Molnlycke Health Care AB
  • CCA Industries Inc.
  • Sisram Medical Ltd.
  • Biodermis
  • Candela Corporation
  • Smith & Nephew plc
  • Scarguard Labs LLC

第31章 附錄

簡介目錄
Product Code: 10180

Key Highlights

The scar treatment market generated a value of USD 23.8 billion in 2023, which will rise to USD 52.8 billion, advancing at over 12.0% CAGR, by 2030.

The rising consciousness regarding scar management, increasing interest of people in having flawless skin, surging need for cosmetic procedures, and evolving medical technology are aiding the industry expansion.

Individuals with long-term disfigurement due to burns, accidents, surgery, or other reasons are searching for effective means to improve their appearance.

The development of different therapies that decrease the scar's visibility and improve the overall skin texture has been enabled by the improvements in medical technology.

The improved cosmetic measures now accessible comprise lasers, chemical peels, microdermabrasion, and dermabrasion.

These advancements have made it possible to offer less intrusive as well as more effective choices to individuals for improving their aesthetics.

There has been an increasing acceptance of scar revision solutions because of the rising consciousness about the different options of treatment accessible.

The public has profited from the information provided by plastic surgeons, skincare experts, and dermatologists about the benefits of under-trial and current skin treatments.

With the arrival of elective surgeries and medical tourism, the count of surgical measures is increasing at a significant pace. This means that now, more potential patients are searching for post-surgery scar treatment.

Market Insights

North America was the largest contributor to the industry in 2023, with a share of approximately 37.8%.

The high disposable salary in North America, which results in a rise in the expenses on personal care products, is a major contributor to the dominance of the regional industry.

In 2023, the U.S. was the largest contributor to the industry in North America, and it is likely to advance at a faster compound annual growth rate during this decade.

The laser category will advance at the highest rate, of 12.7%, during this decade. This will be because laser treatments are more advanced than the currently accessible topical therapies.

Atrophic and acne scars accounted for the largest share of the industry in 2023, with a 40.1% share, and it will remain the largest throughout this decade.

Acne is among of the most common dermatological conditions globally, particularly among adolescents.

Acne occurs because of the clogging of the hair follicles in the skin with sebum, dirt, oil, dead skin cells, and various other impurities, which leads to lesions formation.

Approximately 9.4% of the global population suffers from acne, making it the 8th most prevalent illness in the world.

The keloid and hypertrophic scar category will propel at the fastest CAGR in the years to come. This will be because of the rising volume of surgeries, coupled with the incidence of burn injuries as well as traumatic wounds.

The scar treatment industry is moderately fragmented with the existence of some local players. Players in this industry are trying to enhance their presence by implementing strategies like mergers & acquisitions, partnerships, and investments.

The industry players are also concentrating on sustaining competitive pricing and investing in developing greater and more effective products.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by treatment type
    • 1.4.2. Market size breakdown, by scar type
    • 1.4.3. Market size breakdown, by end user
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Treatment Type (2017-2030)
    • 6.2.1. Topical market revenue, by type (2017-2030)
    • 6.2.2. Surface market revenue, by type (2017-2030)
    • 6.2.3. Laser market revenue, by type (2017-2030)
    • 6.2.4. Injectable market revenue, by type (2017-2030)
  • 6.3. Market Revenue, by Scar Type (2017-2030)
  • 6.4. Market Revenue, by End User (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Treatment Type (2017-2030)
    • 7.2.1. Topical market revenue, by type (2017-2030)
    • 7.2.2. Surface market revenue, by type (2017-2030)
    • 7.2.3. Laser market revenue, by type (2017-2030)
    • 7.2.4. Injectable market revenue, by type (2017-2030)
  • 7.3. Market Revenue, by Scar Type (2017-2030)
  • 7.4. Market Revenue, by End User (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Treatment Type (2017-2030)
    • 8.2.1. Topical market revenue, by type (2017-2030)
    • 8.2.2. Surface market revenue, by type (2017-2030)
    • 8.2.3. Laser market revenue, by type (2017-2030)
    • 8.2.4. Injectable market revenue, by type (2017-2030)
  • 8.3. Market Revenue, by Scar Type (2017-2030)
  • 8.4. Market Revenue, by End User (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Treatment Type (2017-2030)
    • 9.2.1. Topical market revenue, by type (2017-2030)
    • 9.2.2. Surface market revenue, by type (2017-2030)
    • 9.2.3. Laser market revenue, by type (2017-2030)
    • 9.2.4. Injectable market revenue, by type (2017-2030)
  • 9.3. Market Revenue, by Scar Type (2017-2030)
  • 9.4. Market Revenue, by End User (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Treatment Type (2017-2030)
    • 10.2.1. Topical market revenue, by type (2017-2030)
    • 10.2.2. Surface market revenue, by type (2017-2030)
    • 10.2.3. Laser market revenue, by type (2017-2030)
    • 10.2.4. Injectable market revenue, by type (2017-2030)
  • 10.3. Market Revenue, by Scar Type (2017-2030)
  • 10.4. Market Revenue, by End User (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Treatment Type (2017-2030)
    • 11.2.1. Topical market revenue, by type (2017-2030)
    • 11.2.2. Surface market revenue, by type (2017-2030)
    • 11.2.3. Laser market revenue, by type (2017-2030)
    • 11.2.4. Injectable market revenue, by type (2017-2030)
  • 11.3. Market Revenue, by Scar Type (2017-2030)
  • 11.4. Market Revenue, by End User (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Treatment Type (2017-2030)
    • 12.2.1. Topical market revenue, by type (2017-2030)
    • 12.2.2. Surface market revenue, by type (2017-2030)
    • 12.2.3. Laser market revenue, by type (2017-2030)
    • 12.2.4. Injectable market revenue, by type (2017-2030)
  • 12.3. Market Revenue, by Scar Type (2017-2030)
  • 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Treatment Type (2017-2030)
    • 13.2.1. Topical market revenue, by type (2017-2030)
    • 13.2.2. Surface market revenue, by type (2017-2030)
    • 13.2.3. Laser market revenue, by type (2017-2030)
    • 13.2.4. Injectable market revenue, by type (2017-2030)
  • 13.3. Market Revenue, by Scar Type (2017-2030)
  • 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Treatment Type (2017-2030)
    • 14.2.1. Topical market revenue, by type (2017-2030)
    • 14.2.2. Surface market revenue, by type (2017-2030)
    • 14.2.3. Laser market revenue, by type (2017-2030)
    • 14.2.4. Injectable market revenue, by type (2017-2030)
  • 14.3. Market Revenue, by Scar Type (2017-2030)
  • 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Treatment Type (2017-2030)
    • 15.2.1. Topical market revenue, by type (2017-2030)
    • 15.2.2. Surface market revenue, by type (2017-2030)
    • 15.2.3. Laser market revenue, by type (2017-2030)
    • 15.2.4. Injectable market revenue, by type (2017-2030)
  • 15.3. Market Revenue, by Scar Type (2017-2030)
  • 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Treatment Type (2017-2030)
    • 16.2.1. Topical market revenue, by type (2017-2030)
    • 16.2.2. Surface market revenue, by type (2017-2030)
    • 16.2.3. Laser market revenue, by type (2017-2030)
    • 16.2.4. Injectable market revenue, by type (2017-2030)
  • 16.3. Market Revenue, by Scar Type (2017-2030)
  • 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Treatment Type (2017-2030)
    • 17.2.1. Topical market revenue, by type (2017-2030)
    • 17.2.2. Surface market revenue, by type (2017-2030)
    • 17.2.3. Laser market revenue, by type (2017-2030)
    • 17.2.4. Injectable market revenue, by type (2017-2030)
  • 17.3. Market Revenue, by Scar Type (2017-2030)
  • 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Treatment Type (2017-2030)
    • 18.2.1. Topical market revenue, by type (2017-2030)
    • 18.2.2. Surface market revenue, by type (2017-2030)
    • 18.2.3. Laser market revenue, by type (2017-2030)
    • 18.2.4. Injectable market revenue, by type (2017-2030)
  • 18.3. Market Revenue, by Scar Type (2017-2030)
  • 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Treatment Type (2017-2030)
    • 19.2.1. Topical market revenue, by type (2017-2030)
    • 19.2.2. Surface market revenue, by type (2017-2030)
    • 19.2.3. Laser market revenue, by type (2017-2030)
    • 19.2.4. Injectable market revenue, by type (2017-2030)
  • 19.3. Market Revenue, by Scar Type (2017-2030)
  • 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Treatment Type (2017-2030)
    • 20.2.1. Topical market revenue, by type (2017-2030)
    • 20.2.2. Surface market revenue, by type (2017-2030)
    • 20.2.3. Laser market revenue, by type (2017-2030)
    • 20.2.4. Injectable market revenue, by type (2017-2030)
  • 20.3. Market Revenue, by Scar Type (2017-2030)
  • 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Treatment Type (2017-2030)
    • 21.2.1. Topical market revenue, by type (2017-2030)
    • 21.2.2. Surface market revenue, by type (2017-2030)
    • 21.2.3. Laser market revenue, by type (2017-2030)
    • 21.2.4. Injectable market revenue, by type (2017-2030)
  • 21.3. Market Revenue, by Scar Type (2017-2030)
  • 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Treatment Type (2017-2030)
    • 22.2.1. Topical market revenue, by type (2017-2030)
    • 22.2.2. Surface market revenue, by type (2017-2030)
    • 22.2.3. Laser market revenue, by type (2017-2030)
    • 22.2.4. Injectable market revenue, by type (2017-2030)
  • 22.3. Market Revenue, by Scar Type (2017-2030)
  • 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Treatment Type (2017-2030)
    • 23.2.1. Topical market revenue, by type (2017-2030)
    • 23.2.2. Surface market revenue, by type (2017-2030)
    • 23.2.3. Laser market revenue, by type (2017-2030)
    • 23.2.4. Injectable market revenue, by type (2017-2030)
  • 23.3. Market Revenue, by Scar Type (2017-2030)
  • 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Treatment Type (2017-2030)
    • 24.2.1. Topical market revenue, by type (2017-2030)
    • 24.2.2. Surface market revenue, by type (2017-2030)
    • 24.2.3. Laser market revenue, by type (2017-2030)
    • 24.2.4. Injectable market revenue, by type (2017-2030)
  • 24.3. Market Revenue, by Scar Type (2017-2030)
  • 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Treatment Type (2017-2030)
    • 25.2.1. Topical market revenue, by type (2017-2030)
    • 25.2.2. Surface market revenue, by type (2017-2030)
    • 25.2.3. Laser market revenue, by type (2017-2030)
    • 25.2.4. Injectable market revenue, by type (2017-2030)
  • 25.3. Market Revenue, by Scar Type (2017-2030)
  • 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Treatment Type (2017-2030)
    • 26.2.1. Topical market revenue, by type (2017-2030)
    • 26.2.2. Surface market revenue, by type (2017-2030)
    • 26.2.3. Laser market revenue, by type (2017-2030)
    • 26.2.4. Injectable market revenue, by type (2017-2030)
  • 26.3. Market Revenue, by Scar Type (2017-2030)
  • 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Treatment Type (2017-2030)
    • 27.2.1. Topical market revenue, by type (2017-2030)
    • 27.2.2. Surface market revenue, by type (2017-2030)
    • 27.2.3. Laser market revenue, by type (2017-2030)
    • 27.2.4. Injectable market revenue, by type (2017-2030)
  • 27.3. Market Revenue, by Scar Type (2017-2030)
  • 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Treatment Type (2017-2030)
    • 28.2.1. Topical market revenue, by type (2017-2030)
    • 28.2.2. Surface market revenue, by type (2017-2030)
    • 28.2.3. Laser market revenue, by type (2017-2030)
    • 28.2.4. Injectable market revenue, by type (2017-2030)
  • 28.3. Market Revenue, by Scar Type (2017-2030)
  • 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Avita Medical Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Revitol Corporation
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Sonoma Pharmaceuticals Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Molnlycke Health Care AB
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. CCA Industries Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Sisram Medical Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Biodermis
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Candela Corporation
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Smith & Nephew plc
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Scarguard Labs LLC
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports